Navigation Links
Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Date:8/19/2008

EAST SETAUKET, N.Y., Aug. 19 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte filed a joint patent application identifying a biomarker, present in many common cancers, that is a target of drugs being evaluated by Lixte and NINDS for the treatment of brain tumors.

Dr. John S. Kovach, President and CEO of Lixte, said, "Studies with the research team at the Molecular Pathogenesis Unit, Surgical Neurology Branch, NINDS, identified a biomarker that appears to be preferentially targeted by novel anti-cancer drugs currently being evaluated by NINDS and Lixte as new treatments for human brain tumors. Molecular studies revealed that these drugs alter the state of this biomarker in a way that leads to the death of cancer cells. Since the biomarker appears to be important to the survival of several human cancers in addition to brain cancers, studies will be done to determine the effectiveness of targeting the biomarker in other tumor types and as a guide to drug discovery of new anti-cancer compounds."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.

About the National Institute of Neurological Disorders and Stroke (NINDS), (NIH):

NINDS (http://www.ninds.nih.gov) is a component of the National Institutes of Health (NIH), and is the nation's primary supporter of biomedical research on the brain and nervous system.

The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
2. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
3. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
4. Yongye Biotechnology International Announces Second Quarter Results
5. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
6. Yongye Biotechnology International Retains CCG Investor Relations
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. New Book on the Business of Biotechnology
9. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
10. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
11. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... Technologies , a high-technology spin-off of the University of ... during the biggest blackout the nation has ever seen. ... Near-simultaneous events were recorded in New York and Michigan ... across the northeastern United States, with the I-Grid recording ...
... Wisconsin companies recently won CIO magazines CIO ... resourcefulness regarding the use of information technology(IT) within their ... Menasha Corp. each won the award, announced in the ... Manpower CIOs are on the cover of the magazine. ...
... a two-year grant from the state Department of Commerce ... which for years trailed their counterparts in Madison in ... up. Thats good news for Milwaukee - which means ... wants to transform itself from an old-line manufacturing burg ...
Cached Biology Technology:Local Company Records Blackout with Web-Based Monitoring System 2Local Company Records Blackout with Web-Based Monitoring System 3Five Wisconsin Non-Tech Companies Win IT Awards 2Five Wisconsin Non-Tech Companies Win IT Awards 3Five Wisconsin Non-Tech Companies Win IT Awards 4Milwaukee research institutions step up the pace for technology transfer 2
(Date:4/23/2014)... of dementia and affects some 400,000 people in Spain ... One of the reasons for this is the lack ... in nerve transmissions and the loss of memory in ... Institute of Neuroscience at the Universitat Autnoma de Barcelona ... and were able to develop a gene therapy which ...
(Date:4/23/2014)... of social relationships they may be friends, kin, ... From a cognitive perspective, understanding one,s own relationships to ... ("knowing who is nice or not"). Yet, understanding also ... the stage for "political" maneuvers ("knowing who might support ... in the scientific journal Nature Communications . ...
(Date:4/23/2014)... London (April 23, 2014). "I think one can argue that ... well as doing everything else that we canthen we can ... Wigley, one of the world,s foremost climate researchers, in the ... published by SAGE. Refusing to take significant action on climate ... be needed to address the problem, Wigley explains in an ...
Breaking Biology News(10 mins):Loss of memory in Alzheimer's mice models reversed through gene therapy 2Ravens understand the relations among others 2Is nuclear power the only way to avoid geoengineering? 2
... different from what a runner might take on a ... to make life more comfortable for cattle. A ... a pedometer are a few of the tools K-State ... two routine procedures, castration and dehorning. Hans Coetzee, ...
... including nursery and greenhouse producers, landscape services firms, ... during the past two decades, becoming an increasingly ... the Green Industry generated 1.96 million jobs and ... U.S. nursery and greenhouse crops reached $16.9 billion. ...
... the twelfth release in a series of erect-growing, ... Watson) cultivars developed by the University of Arkansas. ... of the Department of Horticulture at the University ... issue of the American Society of Horticultural Science,s ...
Cached Biology News:Veterinarians developing model to help producers, vets make cattle more comfortable 2Veterinarians developing model to help producers, vets make cattle more comfortable 3Results of national nursery survey unveiled 2
... clone d1-174 GenBank Accession Number : ... N-terminal tagged fusion protein corresponding to full ... Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium ... 30% Quality Assurance: routinely evaluated by immunoblot ...
...
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Biology Products: